Stricter Regulations on GLP-1 Drugs to Curb Health Risks

The Indian government is intensifying regulatory surveillance over GLP-1 drugs used for diabetes and obesity due to concerns about unauthorized sales and side effects. These medications, requiring prescription, have been linked to severe health risks if misused. Inspections and stricter enforcement are being implemented to prevent malpractices.

The Indian government has heightened its regulatory measures regarding GLP-1 drugs, which are used to manage type 2 diabetes and obesity. The move is in response to rising concerns over unauthorized sales and the serious side effects that can occur if the drugs are used without medical supervision.

The Central Drugs Standard Control Organization (CDSCO) is intensifying inspections and vigilant oversight. They emphasize that these medications must only be prescribed by qualified specialists and warn that businesses violating these rules will face stringent actions, including license cancellations and legal repercussions.

Aimed at controlling hormonal imbalances, common GLP-1 drugs like Semaglutide and Liraglutide help regulate blood sugar levels and appetite. However, their misuse has been linked to health complications such as pancreatitis and kidney injury, necessitating a crackdown to prevent non-prescription access and misleading promotions.

(With inputs from agencies.)